This post was originally published on this site
Evolus Inc. wants to change how people think of fillers with its newest product line.
The Newport Beach aesthetics company launched Evolysse Form and Evolysse Smooth, which refers to its injectable hyaluronic acid gels. The first two products in the Evolysse collection received Food and Drug Administration approval in February.
Evolus started a campaign called “Drop the F Word” ahead of the April launch of Evolysse, encouraging physicians to stop using the word “filler” due to its association with an unnatural look.
“Prior to launch, we conducted extensive research with both consumers and professionals to better understand market dynamics and identify how Evolysse could be uniquely positioned for success,” Evolus Chief Executive David Moatazedi said during a May 7 earnings call.
“A key insight was a shift in consumer sentiment surrounding the word filler, which has contributed to lower engagement in the category.”
Its strategy seems to be working.
Moatazedi said that Evolysse is outperforming the initial launch of Jeuveau, Evolus’ signature product that competes with Botox from Abbvie Inc.’s Allergan.
“Evolysse is already proving to be a powerful complement to Jeuveau,” he said.
The company aims to launch two additional products, Evolysse Sculpt and Evolysse Lips, in 2026 and 2027, respectively.
Evolus in 2023 first announced it was partnering with French company Symatese Aesthetics to create a line of five dermal fillers.
Preparing for EU Rollout
Evolus also recently announced the publication of its U.S. study for Evolysse Form and Evolysse Smooth.
Findings from the study, published in the Aesthetic Surgery Journal, found that both products demonstrated “statistical superiority” over one of the market leading hyaluronic gels in treating dynamic facial wrinkles and folds.
“One key feature of the Evolysse injectable HA gels that this study and publication highlight is the efficiency of their performance,” Dr. Rui Avelar, chief medical officer and head of R&D at Evolus, said in a statement.
Evolus also received Medical Device Regulation approval in Europe for four unique injectable hyaluronic gels under the brand name Estyme, expanding its presence into the global dermal filler market.
It plans to do a limited rollout of Estyme to select physicians with a broader European launch on track for the second half of 2025, according to the company.
The company anticipates Evolysse and Estyme to contribute between 8% to 10% of total sales for 2025.